当前位置:首页 - 行情中心 - 华恒生物(688639) - 财务分析 - 现金流量表

华恒生物

(688639)

  

流通市值:85.69亿  总市值:85.69亿
流通股本:2.50亿   总股本:2.50亿

现金流量表

报告期2025-12-312025-09-302025-06-302025-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,730,918,428.862,139,169,844.581,412,441,457.52648,660,311.45
  收到的税费返还87,297,402.3778,172,268.5755,598,169.9625,589,077.87
  收到其他与经营活动有关的现金52,650,507.0635,578,875.0324,052,250.34,914,079.81
  经营活动现金流入小计2,870,866,338.292,252,920,988.181,492,091,877.78679,163,469.13
  购买商品、接受劳务支付的现金2,186,529,162.151,717,363,072.231,130,890,211.75538,608,822.3
  支付给职工以及为职工支付的现金321,639,985.93233,611,314.08154,930,521.2693,815,077.99
  支付的各项税费55,282,272.447,546,495.1635,734,492.614,312,265.4
  支付其他与经营活动有关的现金202,868,246.72139,658,595.7195,804,956.426,706,219.17
  经营活动现金流出小计2,766,319,667.22,138,179,477.181,417,360,182.02663,442,384.86
  经营活动产生的现金流量净额104,546,671.09114,741,51174,731,695.7615,721,084.27
二、投资活动产生的现金流量:
  取得投资收益收到的现金900,000---
  处置固定资产、无形资产和其他长期资产收回的现金净额1,187,534.5137,856.717,558.7-
  收到的其他与投资活动有关的现金---560,000
  投资活动现金流入小计2,087,534.5137,856.717,558.7560,000
  购建固定资产、无形资产和其他长期资产支付的现金636,725,336.47394,487,095.37253,699,111.4493,009,462.7
  投资支付的现金2,816,500---
  支付其他与投资活动有关的现金6,001,566.5310,002,257.877,751,377.872,090,000
  投资活动现金流出小计645,543,403404,489,353.24261,450,489.3195,099,462.7
  投资活动产生的现金流量净额-643,455,868.49-404,451,496.54-261,432,930.61-94,539,462.7
三、筹资活动产生的现金流量:
  吸收投资收到的现金5,075,560.445,075,560.445,075,560.44-
  取得借款收到的现金1,717,908,246.631,453,017,760.95792,207,827.21396,621,603.93
  筹资活动现金流入小计1,722,983,807.071,458,093,321.39797,283,387.65396,621,603.93
  偿还债务支付的现金1,186,918,259.96990,237,333.19625,337,333.19311,437,333.19
  分配股利、利润或偿付利息支付的现金110,813,237.66101,748,248.8922,397,131.999,884,947.29
  支付其他与筹资活动有关的现金16,032,937.34150,000--
  筹资活动现金流出小计1,313,764,434.961,092,135,582.08647,734,465.18321,322,280.48
  筹资活动产生的现金流量净额409,219,372.11365,957,739.31149,548,922.4775,299,323.45
四、汇率变动对现金及现金等价物的影响-1,147,319.181,745,348.31,463,668.066,481,912.66
五、现金及现金等价物净增加额-130,837,144.4777,993,102.07-35,688,644.322,962,857.68
  加:期初现金及现金等价物余额414,959,350.9414,959,350.9414,959,350.9414,959,350.9
  期末现金及现金等价物余额284,122,206.43492,952,452.97379,270,706.58417,922,208.58
补充资料:
  净利润123,861,236.18-109,148,765.67-
  资产减值准备13,732,484.87-9,283,681.96-
  固定资产和投资性房地产折旧209,157,496.81-90,878,605.11-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧209,157,496.81-90,878,605.11-
  无形资产摊销5,640,802.57-2,777,323.29-
  长期待摊费用摊销6,239,814.97-2,535,438.33-
  处置固定资产、无形资产和其他长期资产的损失-122,573.32-60,888.58-
  固定资产报废损失1,861,198.12-1,211,845.43-
  财务费用42,685,129.98-18,980,705.3-
  投资损失915,414.66-1,541,975.33-
  递延所得税-24,500,028.45--15,057,860.67-
  其中:递延所得税资产减少-58,757,523.06--20,719,497.63-
    递延所得税负债增加34,257,494.61-5,661,636.96-
  存货的减少-138,942,755.94--111,323,784.44-
  经营性应收项目的减少-73,479,827.55--38,925,797.58-
  经营性应付项目的增加-66,780,968.05--4,484,194.76-
  其他3,881,707.55-3,881,707.55-
  现金的期末余额284,122,206.43-379,270,706.58-
  减:现金的期初余额414,959,350.9-414,959,350.9-
  现金及现金等价物的净增加额-130,837,144.47--35,688,644.32-
公告日期2026-03-182025-10-282025-08-282025-04-23
审计意见(境内)标准无保留意见
TOP↑